During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

For Heart Health Month, Amy Ahnert, MD, discussed the link between cardiovascular disease and breast cancer.

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...